网络药理学和分子对接将Medicarpin确定为一种强大的CASP3和ESR1结合剂,驱动着细胞缩和荷尔蒙依赖的抗癌活性
Yanisa Rattanapan1,2, Sirinya Sitthirak1,3, Aman Tedasen1,3
1Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.
International journal of molecular sciences
|January 10, 2026
概括
梅迪卡尔通过向参与细胞生长和死亡的多个途径,显示出治疗卵巢癌 (OC) 的潜力. 需要进一步的研究来确认其在OC中的抗癌作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 卵巢癌 (OC) 是一种致命的妇科恶性瘤,由于晚期诊断和化学抵抗,其结果不佳.
- 目前的向疗法提供有限的持久反应,突出显示了对新型多向药物的需求.
- 在OC中,天然植物素medicarpin的分子机制尚不清楚.
研究的目的:
- 通过整合性in silico方法阐明medicarpin在卵巢癌中的治疗景观和分子机制.
- 识别OC中medicarpin调节的关键分子标和途径.
主要方法:
- 网络药理学被用来识别OC中的重叠的medicarpin目标.
- 路径丰富分析 (基因本体学和KEGG) 确定了显著丰富的信号路径.
- 分子对接模拟评估了medicarpin与关键标蛋白的结合亲和力.
- 生存分析评估了已识别的枢纽基因的预后意义.
主要成果:
- 确定了107个重叠的目标,形成一个蛋白质-蛋白质相互作用网络,富含酶介导和亡信号.
- 确定了10个枢纽基因,包括CASP3,ESR1和mTOR.
- 梅迪卡尔对CASP3和ESR1的结合稳定,这表明对亡和激素通路的双重调节.
- PI3K-Akt/mTOR和益生菌信号通路得到了显著的丰富.
结论:
- 梅迪卡通过调节激酶驱动和荷尔蒙依赖的途径,在卵巢癌中表现出多目标抗癌潜力.
- 已识别的枢纽基因和通路为medicarpin的治疗作用提供了分子基础.
- 需要进一步的实验验证,以确认medicarpin在OC治疗中的有效性和安全性.
相关概念视频
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
Caspases
13.7K
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
13.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

